[Public Notice+] Cellmat Therapeutics "Chairman Yoon Byung-hak Participates in Capital Increase... Strengthening Responsible Management"

[Asia Economy Reporter Hyunseok Yoo] Cellma Therapeutics announced on the 2nd that it will conduct a third-party allotment paid-in capital increase worth 3 billion KRW targeting YBH Global.

YBH Global is named after the English initials of Chairman Yoon Byung-hak, who is registered as the CEO and largest shareholder. 500,000 new shares are scheduled to be listed, with an expected issue price of 6,000 KRW per share. The payment date is set for the 31st of next month, and the new shares are expected to be listed on September 21.

Chairman Yoon Byung-hak stated, “Through this paid-in capital increase, I intend to devote efforts to overall management not just as a professional manager but through substantial capital investment,” adding, “We plan to focus on the bio-pharmaceutical business with the funds raised.”

Meanwhile, Cellma had previously reduced the third-party allotment paid-in capital increase originally scheduled for 13 billion KRW on the 31st to 5 billion KRW and made an early payment on the 30th of last month. A company official explained, “The early payment was made to resolve concerns about capital erosion and to secure financial stability.”

This content was produced with the assistance of AI translation services.